Global's November 2025 Stock Picks That May Be Trading Below Estimated Value

As global markets grapple with AI-related concerns and fluctuating economic indicators, investors are increasingly focused on identifying opportunities amidst the volatility. In such an environment, stocks that appear undervalued based on their fundamentals may offer potential for those looking to navigate the current market sentiment.

Top 10 Undervalued Stocks Based On Cash Flows

Name	Current Price	Fair Value (Est)	Discount (Est)
Vimi Fasteners (BIT:VIM)	€1.07	€2.12	49.4%
STEICO (XTRA:ST5)	€20.10	€40.10	49.9%
Roche Bobois (ENXTPA:RBO)	€34.80	€69.37	49.8%
Raksul (TSE:4384)	¥1148.00	¥2276.91	49.6%
Nippon Thompson (TSE:6480)	¥706.00	¥1407.35	49.8%
Micro Systemation (OM:MSAB B)	SEK64.60	SEK127.66	49.4%
HMS Bergbau (XTRA:HMU)	€52.00	€103.88	49.9%
Exel Composites Oyj (HLSE:EXL1V)	€0.392	€0.78	49.9%
EcoUp Oyj (HLSE:ECOUP)	€1.32	€2.64	50%
Delivery Hero (XTRA:DHER)	€16.02	€31.79	49.6%

Click here to see the full list of 507 stocks from our Undervalued Global Stocks Based On Cash Flows screener.

We'll examine a selection from our screener results.

Agthia Group PJSC (ADX:AGTHIA)

Overview: Agthia Group PJSC is a company engaged in the food and beverage industry both within the United Arab Emirates and internationally, with a market capitalization of AED3.19 billion.

Operations: Agthia Group PJSC's revenue segments include AED1.50 billion from the Consumer Business Division - Snacks, AED979.93 million from Protein and FV, AED1.28 billion from Water and Food, and AED1.25 billion from the Agri Business Division - Flour and Animal Feed.

Estimated Discount To Fair Value: 36.2%

Agthia Group PJSC is trading at AED 3.84, significantly below its estimated fair value of AED 6.02, suggesting it may be undervalued based on cash flows. Despite a challenging year with reduced net income and profit margins, the company is expected to see substantial earnings growth of approximately 40% annually over the next three years. However, interest payments are not well covered by earnings, and dividend sustainability remains a concern due to coverage issues.

• In light of our recent growth report, it seems possible that Agthia Group PJSC's financial performance will exceed current levels.
• Click here and access our complete balance sheet health report to understand the dynamics of Agthia Group PJSC.

Almoosa Health (SASE:4018)

Overview: Almoosa Health Company is a private healthcare provider in the Kingdom of Saudi Arabia with a market cap of SAR7.96 billion.

Operations: The company's revenue segments include Rehabilitation at SAR162.41 million, Pharmaceuticals at SAR295.83 million, and Medical Services at SAR902.20 million.

Estimated Discount To Fair Value: 41%

Almoosa Health is trading at SAR 179.6, well below its estimated fair value of SAR 304.19, indicating potential undervaluation based on cash flows. The company reported strong earnings growth with net income rising to SAR 154.5 million for the first nine months of 2025, up from SAR 40.4 million a year ago. Recent debt financing of SAR 1.34 billion supports expansion projects but may impact future cash flow flexibility due to repayment obligations.

• Upon reviewing our latest growth report, Almoosa Health's projected financial performance appears quite optimistic.
• Dive into the specifics of Almoosa Health here with our thorough financial health report.

PharmaEssentia (TWSE:6446)

Overview: PharmaEssentia Corporation is a biopharmaceutical company focused on developing treatments for human diseases in Taiwan and internationally, with a market cap of NT$172.90 billion.

Operations: The company generates revenue from the Research and Development of New Drugs segment, amounting to NT$13.82 billion.

Estimated Discount To Fair Value: 48.9%

PharmaEssentia, trading at NT$485.5, is significantly undervalued with an estimated fair value of NT$950.66. The company's earnings grew by 160.3% over the past year, and its revenue is projected to grow at 34.4% annually, outpacing the Taiwan market's growth rate of 13.2%. Recent financial results show a strong increase in net income to TWD 1,473.08 million for Q3 2025 from TWD 719.69 million a year ago, reflecting robust cash flow potential despite high non-cash earnings levels.

• Our expertly prepared growth report on PharmaEssentia implies its future financial outlook may be stronger than recent results.
• Take a closer look at PharmaEssentia's balance sheet health here in our report.

Taking Advantage

• Take a closer look at our Undervalued Global Stocks Based On Cash Flows list of 507 companies by clicking here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com